Equity Overview
Price & Market Data
Price: $40.50
Daily Change: -$0.85 / 2.10%
Daily Range: $40.31 - $41.53
Market Cap: $2,865,921,536
Daily Volume: 538,645
Performance Metrics
1 Week: -6.63%
1 Month: -9.58%
3 Months: 40.33%
6 Months: 6.02%
1 Year: 3.55%
YTD: 1.54%
Company Details
Employees: 188
Sector: Health technology
Industry: Biotechnology
Country:
Details
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.